<DOC>
	<DOCNO>NCT01113970</DOCNO>
	<brief_summary>This study Phase I/II trial novel Indibulin dosing schedule treatment metastatic breast cancer . Eligible patient measurable non-measurable , metastatic unresectable , locally advanced breast cancer may receive number prior therapy disease . It expect Phase I portion enroll 20 patient Phase II portion enroll 45 patient .</brief_summary>
	<brief_title>Study Novel Indibulin Dosing Schedule Treatment Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Histologic cytologic confirmation invasive carcinoma breast . Clinical evidence metastatic disease locally advanced disease amenable curative therapy . Measurable nonmeasurable lesion accord RECIST Version 1.1 2009 . Any number prior endocrine , biologic chemotherapy regimen permit . All previous chemotherapy biologic therapy must discontinue least 3 week prior begin study drug . Endocrine therapy may use concurrently protocol treatment . All acute toxic effect ( exclude alopecia neuropathy ) prior therapy must resolve NCI CTC ( version 4.0 ) Grade ≤ 1 baseline Prior radiation therapy permit . ECOG performance status 0 , 1 2 . Age ≥ 18 year Life expectancy ≥ 12 week Patients HER2positive ( IHC 3+ FISHamplified ) breast cancer must receive trastuzumab contradiction receive HER2 target therapy ( abnormal leave ventricular ejection fraction ) determine treat physician . Adequate bone marrow , liver renal function assess follow laboratory requirement : Creatinine ≤ 1.5x upper limit normal ( ULN ) Total bilirubin ≤ 1.5x ULN ALT AST ≤ 2.5x ULN ANC ≥ 1.5 x10 ( 9 ) /L Platelets ≥ 100 x10 ( 9 ) /L Hemoglobin ≥ 9g/dL Subjects childbearing potential must agree use barrier method contraception throughout study 3 month study drug administration . Pregnant nursing woman may participate . Serious , uncontrolled , concurrent infection . Patients symptomatic CNS metastasis remain untreated radiation therapy exclude trial . The presence asymptomatic , previously irradiate , stable brain metastasis least 3 month ground trial exclusion . Presence uncontrolled gastrointestinal malabsorption syndrome . Any chemotherapy , radiotherapy breast cancer direct biologic therapy study within 3 week study start . Mitomycin C nitrosureas give within 6 week study entry . No washout period require hormonal therapy . Concurrent radiation therapy permit treatment protocol . History invasive second primary malignancy diagnose within previous 3 year , except Stage I endometrial cervical carcinoma prostate carcinoma treat surgically , nonmelanoma skin cancer . Any medical , psychological social condition may interfere subject 's ability safely participate study . Unwillingness give write informed consent unwillingness participate inability comply protocol duration study . Willingness ability comply schedule visit , treatment plan , laboratory test study procedure necessary participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>Indibulin</keyword>
	<keyword>unresectable , locally advanced breast cancer</keyword>
</DOC>